- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Servier shells out $210M upfront to license Ideaya's potential first-in-class PKC inhibitor outside the US | ||
| Di | Boston biotech Radiance offers China firm $1B-plus for rights to next-gen ADC | ||
| Di | As Cytokinetics awaits FDA approval decision, phase 3 cardio win sends stock soaring | ||
| Di | After strategic pivot, Editas lays out plan to target high cholesterol with gene editing | ||
| Di | Amgen to build $600M R&D site, hire hundreds in California | ||
| Di | Royalty bestows Zenas with $300M deal to push autoimmune asset across FDA finish line | ||
| Di | Vertex forges $2B-plus alliance with Enlaza to create new autoimmune drugs, improve conditioning methods | ||
| Di | Novartis takes another shot at alpha-synuclein with $2.2B Arrowhead CNS deal | ||
| Di | Merck dives into regulatory talks after oral PCSK9 delivers 3rd phase 3 win | ||
| Di | Zymeworks drops clinical-stage T-cell engager after assessing benefit-risk profile | ||
| Di | Chasing pharma heavyweights, Upstream posts phase 2 sinusitis win but stock flows downhill | ||
| Di | Lilly ends 2 of 3 midstage trials for oral GLP-1 contender naperiglipron | ||
| Mo | AstraZeneca gears up for FDA filing after sharing details of baxdrostat's hypertension success | ||
| Mo | Roche sees Alnylam hypertension RNAi drug flunk trial but still plans phase 3 push | ||
| Fr | Zydus' phase 3 liver disease win tees up filing to challenge Gilead and Ipsen | ||
| Fr | Fosun rises again, inking 3rd inflammatory disease deal in 3 weeks | ||
| Fr | BeOne's BCL2 drug hits primary endpoint, setting stage for filings to take up blood cancer mantle | ||
| Do | Months after layoffs, AbbVie-partnered protein degrader specialist Plexium raises $60M | ||
| Do | FDA considers noninvasive liver endpoint for clinical trials, sending MASH biotechs' shares up | ||
| Do | Flagship taps IQVIA as biotech support for company fleet | ||
| Do | Prothena's Alzheimer's trial hit by ARIA showstopper, resulting in 'non-competitive' profile | ||
| 27.08. | Exelixis to lay off 130 employees, shut down Pennsylvania site in post-pandemic downsizing | ||
| 27.08. | Amylyx axes rare disease program after Relyvrio fails to beat placebo | ||
| 27.08. | Nykode, after losing Genentech pact and laying off staff, bets future on phase 2 cancer trial | ||
| 27.08. | Wugen woos VCs, landing $115M to bring fratricide-resistant CAR-T cell therapy to market |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .